Fatema ElAmrawy

Fatema ElAmrawy

Auto-generated profile, based on publicly available information

Fatema ElAmrawy

Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Breast Cancer: Basic and Clinical Research
Verified
Journal Article
Open access
MNMohamed I. Nounou
Mohamed I. Nounou
FEFatema ElAmrawy
Fatema ElAmrawy
NANada Ahmed
Nada Ahmed
KAKamilia Abdelraouf
Kamilia Abdelraouf
SGSatyanarayana Goda
Satyanarayana Goda
HSHussaini Syed-Sha-Qhattal
Hussaini Syed-Sha-Qhattal
Breast cancer is the most prevalent cancer among women worldwide. However, increased survival is due to the dramatic advances in the screening methods, early diagnosis, and breakthroughs in treatments. Over the course of the last decade, many acquisitions have taken place in this critical field of research in the pharmaceutical industry. Advances in molecular biology and pharmacology aided in better understanding of breast cancer, enabling the design of smarter therapeutics able to target cancer and respond to its microenvironment efficiently. Patents and research papers investigating diagnosis and treatment strategies for breast cancer using novel technologies have been surveyed for the past 15 years. Various nanocarriers have been introduced to improve the therapeutic efficacy of anticancer drugs, including liposomes, polymeric micelles, quantum dots, nanoparticles, and dendrimers. This review provides an overview of breast cancer, conventional therapy, novel technologies in the management of breast cancer, and rational approaches for targeting breast cancer. Highlights: Breast cancer is the most common cancer in women worldwide. However, survival rates vary widely, optimistically heading toward a positive trend. Increased survival is due to the drastic shift in the screening methods, early diagnosis, and breakthroughs in treatments. Different strategies of breast cancer classification and staging have evolved over the years. Intrinsic (molecular) subtyping is essential in clinical trials and well understanding of the disease. Many novel technologies are being developed to detect distant metastases and recurrent disease as well as to assess response to breast cancer management. Intensive research efforts are actively ongoing to take novel breast cancer therapeutics to potential clinical application. Most of the recent research papers and patents discuss one of the following strategies: the development of new drug entities that specifically target the breast tumor cells; tailor designing a novel carrier system that can multitask and multifunction as a drug carrier, targeting vehicle and even as a diagnostic tool, direct conjugation of a therapeutic drug moiety with a targeting moiety, diagnostic moiety or pharmacokinetics altering moiety; or the use of innovative nontraditional approaches such as genetic engineering, stem cells, or vaccinations.

1 January 2015 in Healthcare Informatics Research
Verified
Journal Article
Open access
PDF file
FEFatema El-Amrawy
Fatema El-Amrawy
MNMohamed Ismail Nounou
Mohamed Ismail Nounou
El-Amrawy F, et al. Healthc Inform Res. 2015 Oct;21(4):315-320. http://dx.doi.org/10.4258/hir.2015.21.4.315

26 July 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
TTTori B. Terrell-Hall
Tori B. Terrell-Hall
MNMohamed Ismail Nounou
Mohamed Ismail Nounou
FEFatema El-Amrawy
Fatema El-Amrawy
JGJessica Griffith
Jessica Griffith
Paul LockmanPaul Lockman
Paul Lockman
Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer

25 February 2016 in Journal of Dietary Supplements
Verified
Journal Article
Closed access
PDF file
FEFatema ElAmrawy
Fatema ElAmrawy
GEGhada ElAgouri
Ghada ElAgouri
OEOla Elnoweam
Ola Elnoweam
SASamar Aboelazayem
Samar Aboelazayem
EFElMohanad Farouk
ElMohanad Farouk
MNMohamed I. Nounou
Mohamed I. Nounou
Erectile dysfunction prevalence globally is noticeably high. This is accompanied by an increase in the use of nutraceuticals for male enhancement. However, the global market is invaded by counterfeit and adulterated nutraceuticals claimed to be of natural origin sold with a therapeutic claim. The objective of this article is to review male enhancement nutraceuticals worldwide with respect to claim, adulterants, and safety. The definition of such products is variable across countries. Thus, the registration procedures differ as well. This facilitates the manipulation of the process, which leads to widespread adulterated and counterfeit products without control. The tele-advertisement and Internet pharmacies aided the widespread sale of male enhancement nutraceuticals, unfortunately, the spurious ones. Finally, based on literature, most of these products were found to be adulterated with active pharmaceutical ingredients (API) and mislabeled as being natural. These products represent a major health hazard for consumers due to lack of clear regulations.

1 August 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
GEGhada ElAgouri
Ghada ElAgouri
FEFatema ElAmrawy
Fatema ElAmrawy
AEAhmed ElYazbi
Ahmed ElYazbi
AEAhmed Eshra
Ahmed Eshra
MNMohamed I. Nounou
Mohamed I. Nounou

1 January 2018 in Current Drug Safety
Verified
Journal Article
Closed access
PDF file
MNMohamed Ismail Nounou
Mohamed Ismail Nounou
GHGhada El Haddad
Ghada El Haddad
FAFatema El Amrawy
Fatema El Amrawy
OGOla El Gaddar
Ola El Gaddar
Ahmed El-YazbiAhmed El-Yazbi
Ahmed El-Yazbi
AEAhmed Eshra
Ahmed Eshra
Introduction: Due to the chaos in the legislation in the Middle East, male enhancement nutraceuticals may be sold without any registration or evaluation. These products need to be evaluated with respect to safety and efficacy. Furthermore, cultural and social considerations in the Middle East prevent the use of international evaluations schemes for erectile dysfunction. Aim: Evaluating the safety and efficacy parameters of generic and nutraceutical products for erectile dysfunction in the Middle East through a custom-designed, representable and simple system tailored to the regional culture. Methods: 74 healthy male volunteers were enrolled into a comparative, simple randomized, single dose, double blind, and crossover clinical study incorporated with a tailored-designed questionnaire. Safety assessment included laboratory analysis for liver functions and measuring blood pressure. Main Outcome Measures: Subjective data regarding safety and efficacy were assessed from the validated questionnaire. Blood pressure was measured. Blood samples were collected to assess the drug/adulterants concentration and liver and kidney functions. Results: All tested nutraceuticals showed undeclared Sildenafil citrate in patients. Questionnaire results showed high inter-patient variability with respect to efficacy and comparable safety profile compared to Viagra (R). Conclusion: The validated tailored-designed questionnaire effectively assessed the efficacy and safety of male enhancement products. The male enhancement nutraceuticals, sold in Egypt, claimed to be 100% natural are adulterated and of questionable safety profile.